Introduction
Active pharmaceutical ingredient (API) is a biologically active pharmaceutical drug. API can be obtained by a synthetic process or from natural sources. The increasing occurrence of chronic diseases, rising acceptance, and uptake of pharmaceuticals, growth in abbreviated new drug applications (ANDA), and the growing importance of generics are expected to drive market growth. For instance, according to the report published by the Centers for Disease Control and Prevention (CDC), nearly 92.1 million adults in the US dealt with at least one type of cardiovascular diseases in 2017. However, stringent regulatory policies and adverse drug price control policies across numerous countries may hamper the growth of the market.
The global active pharmaceutical ingredient market is expected to reach to a market value of USD 215,125.4 million by 2023 from USD 161,143.2 million in 2017 and is expected to register a CAGR of 4.93% during the forecast period from 2018 to 2023. In 2016, the market was led by the Americas with a 40.7% share, followed by Europe and Asia-Pacific with shares of 27.0% and 24.8%, respectively. The increasing burden of chronic diseases has been observed in different parts of the world which has upsurge the growth of the market.
The global active pharmaceutical ingredients market is segmented by manufacturing process, by type of synthesis, by API formulation, by application, by molecule, and by region.
The global active pharmaceutical ingredients market, by manufacturing process, is segmented into captive manufacturing and contract manufacturing.
The global active pharmaceutical ingredients market, by type of synthesis, is segmented into synthetic and biotech.
The global active pharmaceutical ingredients market, by API formulation, is segmented into generic API and innovative API.
By application, the global active pharmaceutical ingredients market is segmented into cardiovascular disease, oncology, neurological disorders, orthopedic disorders, respiratory, gastrointestinal disorders, urology, and others.
By molecule, the global active pharmaceutical ingredients market is segmented into small molecule and large molecule.
The global active pharmaceutical ingredient market is expected to reach to a market value of USD 215,125.4 million by 2023 from USD 161,143.2 million in 2017 and is expected to register a CAGR of 4.93% during the forecast period from 2018 to 2023.
Key Players
Sanofi, Bayer AG, Pfizer Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, Merck & Co., Inc, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc (GSK), Novartis AG, Eli Lilly and Company, and Teva Pharmaceutical Industries Ltd, and others.
Study objectives
• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the active pharmaceutical ingredients market
• To provide insights into factors affecting the market growth
• To analyze the global active pharmaceutical ingredients market based on various tools such as supply chain analysis and Porter’s five force analysis
• To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
• To provide country-level analysis of the market with respect to current market size and future perspective
• To provide country-level analysis of the market for segments by manufacturing process, by type of synthesis, by API formulation, by application, by molecule, and by region
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the active pharmaceutical ingredients market
Target Audience
• Pharmaceutical and Biotechnology Companies
• Research and Development (R&D) Companies
• Government Research Institutes
• Academic Institutes and Universities
Key Findings
• The global active pharmaceutical ingredients market is expected to reach USD 215,125.4 million by 2023 from USD 161,143.2 million in 2017 and is expected to register a CAGR of 4.93% during the forecast period from 2018 to 2023.
• On the basis of manufacturing process, the captive manufacturing segment is expected to account for the largest market share at a CAGR of 4.78% by 2023
• Based on type of synthesis, the synthetic segment is expected to account for the largest market share at a CAGR of 4.89% by 2023
• Based on API formulation, the generic API segment is expected to account for the largest market share at a CAGR of 4.62% by 2023
• Based on application, the cardiovascular disease segment is expected to account for the largest market share at a CAGR of 3.74% by 2023
• Based on molecule, the small molecule segment is expected to account for the largest market share at a CAGR of 4.89% by 2023
• The Americas is expected to hold the largest share of the global active pharmaceutical ingredients market at a CAGR of 4.74% by 2023
• Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 5.27% by 2023
Regional Analysis
• Americas
o North America
US
Canada
o South America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa
Table of Contents:
1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 List of Assumptions
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Introduction
4.1.1 Drivers
4.1.1.1 Increasing occurrences of chronic diseases
4.1.1.2 Growth in Abbreviated New Drug Applications (ANDA)
4.1.1.3 Rising acceptance and uptake of biopharmaceuticals
4.1.1.4 Growing importance of generics
4.1.2 Restraints
4.1.2.1 Stringent regulatory policies
4.1.2.2 Adverse drug price control policies across numerous countries
4.1.3 Opportunities
4.1.3.1 Emerging biosimilar market
4.2 Increasing scope for high-potency active pharmaceutical ingredients
4.3 Macroeconomic indicators
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 Research &Development
5.2.2 Manufacturing
5.2.3 Distribution
5.2.4 Marketing & Sales
5.2.5 Post-Sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
6 Global Active Pharmaceutical Ingredients Market, by Manufacturing Process
6.1 Introduction
6.1.1 Captive Manufacturing
6.1.2 Contract Manufacturing
7 Global Active Pharmaceutical Ingredients Market, by Type of Synthesis
7.1 Introduction
7.2 Synthetic
7.3 Biotech
7.3.1 Monoclonal Antibodies
7.3.2 Recombinant proteins
7.3.3 Vaccines
7.3.4 Others
8 Global Active Pharmaceutical Ingredients Market, by API Formulation
8.1 Introduction
8.2 Generic API
8.3 Branded/ Innovative API
9 Global Active Pharmaceutical Ingredients Market, by Application
9.1 Introduction
9.2 Cardiovascular Disease
9.3 Oncology
9.4 Neurological Disorders
9.5 Orthopedic Disorders
9.6 Respiratory
9.7 Gastrointestinal Disorders
9.8 Urology
9.9 Others
10 Global Active Pharmaceutical Ingredients Market, by Molecule
10.1 Introduction
10.2 Molecule
10.3 Large Molecule
10.4 Small Molecule
11 Global Active Pharmaceutical Ingredients Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 U.K.
11.3.1.4 Italy
11.3.1.5 Spain
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Asia Pacific
11.4.2 Japan
11.4.3 China
11.4.4 India
11.4.5 Australia
11.4.6 Republic of Korea
11.4.7 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1 Middle East and Africa
11.5.2 Middle East
11.5.2.1 Saudi Arabia
11.5.3 Africa
11.5.3.1 North Africa
12 Competitive Landscape
12.1 Company Market Share Analysis
12.1.1 Introduction
12.2 Merger and Acquisition
12.3 Major Strategies adopted by market players
12.4 Competitive Landscape
12.4.1 Introduction
12.4.2 Strategic Partnership
12.5 Key Developments
12.6 Potential Molecules
13 Company Profiles
13.1 Sanofi
13.1.1 Company Overview
13.1.2 Financial Overview
13.1.3 Products Offering
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.1.6 Key Strategy
13.2 Bayer AG
13.2.1 Company Overview
13.2.2 Financial Overview
13.2.3 Products Offering
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.2.6 Key Strategy
13.3 Pfizer Inc.
13.3.1 Company Overview
13.3.2 Financial Overview
13.3.3 Products Offering
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.3.6 Key Strategy
13.4 F. Hoffmann-La Roche AG
13.4.1 Company Overview
13.4.2 Financial Overview
13.4.3 Products Offering
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.4.6 Key Strategy
13.5 Abbott Laboratories
13.5.1 Company Overview
13.5.2 Financial Overview
13.5.3 Products Offering
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.5.6 Key Strategy
13.6 Merck & Co., Inc.
13.6.1 Company Overview
13.6.2 Financial Overview
13.6.3 Products Offering
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.6.6 Key Strategy
13.7 Boehringer Ingelheim GmbH
13.7.1 Company Overview
13.7.2 Financial Overview
13.7.3 Products Offering
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.7.6 Key Strategy
13.8 Glaxosmithkline Plc (GSK)
13.8.1 Company Overview
13.8.2 Financial Overview
13.8.3 Products Offering
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.8.6 Key Strategy
13.9 Novartis AG
13.9.1 Company Overview
13.9.2 Financial Overview
13.9.3 Products Offering
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.9.6 Key Strategy
13.1 Eli Lilly and Company
13.10.1 Company Overview
13.10.2 Financial Overview
13.10.3 Products Offering
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.10.6 Key Strategy
13.11 Teva Pharmaceutical Industries Ltd
13.11.1 Company Overview
13.11.2 Financial Overview
13.11.3 Products Offering
13.11.4 Key Developments
13.11.5 SWOT Analysis
13.11.6 Key Strategy
14 Conclusion
14.1 Key Findings
14.1.1 CEO’s Viewpoint
14.1.2 Unmet Needs
14.1.3 Key Companies to Watch
14.1.4 Prediction
15 Appendix
15.1 Discussion Blue Print
15.1.1 References
1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 List of Assumptions
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Introduction
4.1.1 Drivers
4.1.1.1 Increasing occurrences of chronic diseases
4.1.1.2 Growth in Abbreviated New Drug Applications (ANDA)
4.1.1.3 Rising acceptance and uptake of biopharmaceuticals
4.1.1.4 Growing importance of generics
4.1.2 Restraints
4.1.2.1 Stringent regulatory policies
4.1.2.2 Adverse drug price control policies across numerous countries
4.1.3 Opportunities
4.1.3.1 Emerging biosimilar market
4.2 Increasing scope for high-potency active pharmaceutical ingredients
4.3 Macroeconomic indicators
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 Research &Development
5.2.2 Manufacturing
5.2.3 Distribution
5.2.4 Marketing & Sales
5.2.5 Post-Sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
6 Global Active Pharmaceutical Ingredients Market, by Manufacturing Process
6.1 Introduction
6.1.1 Captive Manufacturing
6.1.2 Contract Manufacturing
7 Global Active Pharmaceutical Ingredients Market, by Type of Synthesis
7.1 Introduction
7.2 Synthetic
7.3 Biotech
7.3.1 Monoclonal Antibodies
7.3.2 Recombinant proteins
7.3.3 Vaccines
7.3.4 Others
8 Global Active Pharmaceutical Ingredients Market, by API Formulation
8.1 Introduction
8.2 Generic API
8.3 Branded/ Innovative API
9 Global Active Pharmaceutical Ingredients Market, by Application
9.1 Introduction
9.2 Cardiovascular Disease
9.3 Oncology
9.4 Neurological Disorders
9.5 Orthopedic Disorders
9.6 Respiratory
9.7 Gastrointestinal Disorders
9.8 Urology
9.9 Others
10 Global Active Pharmaceutical Ingredients Market, by Molecule
10.1 Introduction
10.2 Molecule
10.3 Large Molecule
10.4 Small Molecule
11 Global Active Pharmaceutical Ingredients Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 U.K.
11.3.1.4 Italy
11.3.1.5 Spain
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Asia Pacific
11.4.2 Japan
11.4.3 China
11.4.4 India
11.4.5 Australia
11.4.6 Republic of Korea
11.4.7 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1 Middle East and Africa
11.5.2 Middle East
11.5.2.1 Saudi Arabia
11.5.3 Africa
11.5.3.1 North Africa
12 Competitive Landscape
12.1 Company Market Share Analysis
12.1.1 Introduction
12.2 Merger and Acquisition
12.3 Major Strategies adopted by market players
12.4 Competitive Landscape
12.4.1 Introduction
12.4.2 Strategic Partnership
12.5 Key Developments
12.6 Potential Molecules
13 Company Profiles
13.1 Sanofi
13.1.1 Company Overview
13.1.2 Financial Overview
13.1.3 Products Offering
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.1.6 Key Strategy
13.2 Bayer AG
13.2.1 Company Overview
13.2.2 Financial Overview
13.2.3 Products Offering
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.2.6 Key Strategy
13.3 Pfizer Inc.
13.3.1 Company Overview
13.3.2 Financial Overview
13.3.3 Products Offering
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.3.6 Key Strategy
13.4 F. Hoffmann-La Roche AG
13.4.1 Company Overview
13.4.2 Financial Overview
13.4.3 Products Offering
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.4.6 Key Strategy
13.5 Abbott Laboratories
13.5.1 Company Overview
13.5.2 Financial Overview
13.5.3 Products Offering
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.5.6 Key Strategy
13.6 Merck & Co., Inc.
13.6.1 Company Overview
13.6.2 Financial Overview
13.6.3 Products Offering
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.6.6 Key Strategy
13.7 Boehringer Ingelheim GmbH
13.7.1 Company Overview
13.7.2 Financial Overview
13.7.3 Products Offering
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.7.6 Key Strategy
13.8 Glaxosmithkline Plc (GSK)
13.8.1 Company Overview
13.8.2 Financial Overview
13.8.3 Products Offering
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.8.6 Key Strategy
13.9 Novartis AG
13.9.1 Company Overview
13.9.2 Financial Overview
13.9.3 Products Offering
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.9.6 Key Strategy
13.1 Eli Lilly and Company
13.10.1 Company Overview
13.10.2 Financial Overview
13.10.3 Products Offering
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.10.6 Key Strategy
13.11 Teva Pharmaceutical Industries Ltd
13.11.1 Company Overview
13.11.2 Financial Overview
13.11.3 Products Offering
13.11.4 Key Developments
13.11.5 SWOT Analysis
13.11.6 Key Strategy
14 Conclusion
14.1 Key Findings
14.1.1 CEO’s Viewpoint
14.1.2 Unmet Needs
14.1.3 Key Companies to Watch
14.1.4 Prediction
15 Appendix
15.1 Discussion Blue Print
15.1.1 References
List of Tables:
TABLE 1 MARKET SYNOPSIS
TABLE 2 LIST OF ASSUMPTIONS
TABLE 3 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 4 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CAPTIVE MANUFACTURING, BY REGION,
2015–2023 (USD MILLION)
TABLE 5 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING, BY REGION
2015–2023 (USD MILLION)
TABLE 6 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 7 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY SYNTHETIC, 2015–2023 (USD MILLION)
TABLE 8 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOLOGICAL, 2015–2023 (USD MILLION)
TABLE 9 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION
2015–2023 (USD MILLION)
TABLE 10 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT PROTEINS, BY REGION,
2015–2023 (USD MILLION)
TABLE 11 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH, BY VACCINES, 2015–2023 (USD MILLION)
TABLE 12 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHERS, BY VACCINES, 2015–2023 (USD MILLION)
TABLE 13 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 14 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC API, BY REGION, 2015–2023 (USD MILLION)
TABLE 15 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BRANDED/ INNOVATIVE API, BY REGION,
2015–2023 (USD MILLION)
TABLE 16 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 17 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION,
2015–2023 (USD MILLION)
TABLE 18 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2015–2023 (USD MILLION)
TABLE 19 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION,
2015–2023 (USD MILLION)
TABLE 20 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2015–2023 (USD MILLION)
TABLE 21 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY, BY REGION, 2015–2023 (USD MILLION)
TABLE 22 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION,
2015–2023 (USD MILLION)
TABLE 23 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR UROLOGY, BY REGION, 2015–2023 (USD MILLION)
TABLE 24 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER APPLICATION, BY REGION,
2015–2023 (USD MILLION)
TABLE 25 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 26 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR LARGE MOLECULE, BY REGION, 2015–2023 (USD MILLION)
TABLE 27 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SMALL MOLECULE, BY REGION, 2015–2023 (USD MILLION)
TABLE 28 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2015–2023 (USD MILLION)
TABLE 29 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2015–2023 (USD MILLION)
TABLE 30 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 31 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 32 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 33 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 34 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 35 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 36 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2014-2023 (USD MILLION)
TABLE 37 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,
2015–2023 (USD MILLION)
TABLE 38 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 39 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 40 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 41 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 42 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 43 U.S. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 44 U.S. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 45 U.S. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 46 U.S. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 47 U.S. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 48 U.S. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 49 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 50 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 51 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 52 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 53 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 54 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 55 SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,
2015–2023 (USD MILLION)
TABLE 56 SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 57 SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 58 SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 59 SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 60 SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 61 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2015–2023 (USD MILLION)
TABLE 62 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 63 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 64 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 65 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 66 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 67 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 68 WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,
2015–2023 (USD MILLION)
TABLE 69 WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 70 WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 71 WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 72 WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 73 WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 74 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 75 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 76 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 77 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 78 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 79 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 80 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 81 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 82 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 83 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 84 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 85 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 86 U.K ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 87 U.K ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 88 U.K ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 89 U.K ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 90 U.K ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 91 U.K ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 92 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 93 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 94 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 95 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 96 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 97 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 98 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 99 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 100 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 101 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 102 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 103 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 104 REST OF WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,
2015–2023 (USD MILLION)
TABLE 105 REST OF WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS,
2015–2023 (USD MILLION)
TABLE 106 REST OF WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 107 REST OF WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION,
2015–2023 (USD MILLION)
TABLE 108 REST OF WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 109 REST OF WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 110 EASTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,
2015–2023 (USD MILLION)
TABLE 111 EASTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 112 EASTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 113 EASTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 114 EASTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 115 EASTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 116 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2015–2023 (USD MILLION)
TABLE 117 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 118 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 119 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 120 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 121 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 122 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 123 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 124 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 125 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 126 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 127 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 128 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 129 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 130 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 131 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 132 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 133 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 134 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 135 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 136 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 137 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 138 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 139 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 140 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 141 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 142 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 143 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 144 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 145 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 146 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 147 REPUBLIC OF KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,
2015–2023 (USD MILLION)
TABLE 148 REPUBLIC OF KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 149 REPUBLIC OF KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 150 REPUBLIC OF KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 151 REPUBLIC OF KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 152 REPUBLIC OF KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 153 REST OF ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,
2015–2023 (USD MILLION)
TABLE 154 REST OF ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 155 REST OF ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 156 REST OF ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 157 REST OF ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 158 REST OF ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 159 MIDDLE EAST & NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY CONSUMPTION,
2015–2023 (USD MILLION)
TABLE 160 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2015–2023 (USD MILLION)
TABLE 161 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,
2015–2023 (USD MILLION)
TABLE 162 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS,
2015–2023 (USD MILLION)
TABLE 163 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 164 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION,
2015–2023 (USD MILLION)
TABLE 165 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 166 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 167 MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 168 MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 169 MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 170 MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 171 MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 172 MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 173 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY CONSUMPTION, 2015–2023 (USD MILLION)
TABLE 174 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 175 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 176 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 177 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 178 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 179 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 180 AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2015–2023 (USD MILLION)
TABLE 181 AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 182 AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 183 AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 184 AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 185 AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 186 NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,
2015–2023 (USD MILLION)
TABLE 187 NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2015–2023 (USD MILLION)
TABLE 188 NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2015–2023 (USD MILLION)
TABLE 189 NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2015–2023 (USD MILLION)
TABLE 190 NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2015–2023 (USD MILLION)
TABLE 191 NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2015–2023 (USD MILLION)
TABLE 192 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY DEVELOPMENT
List of Figures:
FIGURE 1 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET: MARKET STRUCTURE
FIGURE 2 RESEARCH PROCESS OF MRFR
FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH
FIGURE 4 DRIVERS & RESTRAINTS: GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET
FIGURE 6 SUPPLY CHAIN: ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET
FIGURE 7 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2017 (% SHARE)
FIGURE 8 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2017 & 2023 (USD MILLION)
FIGURE 9 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 2017 (% SHARE)
FIGURE 10 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017 & 2023 (USD MILLION)
FIGURE 11 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION 2017 (% SHARE)
FIGURE 12 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2017 & 2023 (USD MILLION)
FIGURE 13 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION 2017 (% SHARE)
FIGURE 14 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2014 TO 2023 (USD MILLION)
FIGURE 15 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE 2017 (% SHARE)
FIGURE 16 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2014 TO 2023 (USD MILLION)
FIGURE 17 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017 & 2023 (USD MILLION)
FIGURE 18 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017 (%)
FIGURE 19 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY COUNTRY, 2017 (% SHARE)
FIGURE 20 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2017 (%)
FIGURE 21 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2017 (%)
FIGURE 22 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2017 (%)
FIGURE 23 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, MARKET SHARE ANALYSIS 2017 (%)
FIGURE 24 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET COMPETITIVE LANDSCAPE (%)
Sanofi
Bayer AG
Pfizer Inc.
F. Hoffmann-La Roche AG
Abbott Laboratories
Merck & Co., Inc
Boehringer Ingelheim GmbH
Glaxosmithkline Plc (GSK)
Novartis AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd,
and others
